Tracer library / [68Ga]Ga-DOTA-TOC
[68Ga]Ga-DOTA-TOC
Also written as [68Ga]DOTATOC; [68Ga]Ga-DOTA-TOC; [68Ga]Ga-DOTATOC; [Ga-68]DOTATOC; [Ga-68]Ga-DOTA-TOC; [Ga-68]Ga-DOTATOC; DOTA-TOC
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- PET
- Production route
- —
- Stage
- Approved
- Syntheses indexed
- 40
What it is
- Compound class
- Radiolabelled somatostatin analogue peptide (octreotide/DOTA-Tyr3-octreotide derivative)
- Target / mechanism
- Somatostatin receptor, predominantly subtype 2 (SSTR2) PMID 29243585
- Clinical application
- PET imaging of somatostatin-receptor-expressing neuroendocrine tumours (NET) PMID 29243585
- Theranostic pair
- [177Lu]Lu-DOTA-TOC
Regulatory status
- FDA
- 2019, Gallium Ga 68 Edotreotide Injection, University of Iowa Health Care (UIHC) PET Imaging FDA (Drugs@FDA/openFDA): NDA210828, approved 2019-08-21
- EMA (centralised)
- 2016, SomaKit TOC, Advanced Accelerator Applications (Novartis group) EMA medicines register export (2026-09-09): EMEA/H/C/004140, 'Authorised'; date of authorisation 8 Dec 2016 (EMA EPAR overview)
- Other approvals
- —
- Brand names
- Gallium Ga 68 Edotreotide (US); SomaKit TOC (EU)
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| iMiDEV PMB-Alcen | vendor cassette | SPE | 46 ± 7 decay-corrected | 99.6 ± 0.2% HPLC | DOTA-TOC MedChemTronica, Sollentuna, Sweden | 38091157 2023 EJNMMI Radiopharm Chem Microfluidic-based production of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC using the cassette-based iMiDEV™ microfluidic radiosynthesizer - For [68Ga]Ga-DOTA-TOC, RCYdc was 46 ± 7% (n = 3) |
| Scintomics GRP / GRP-3V Scintomics | — | SPE | — | — | DOTATOC ABX | 32410136 2020 EJNMMI Radiopharm Chem The syntheses were performed using a GRP® synthesis module from Scintomics (Fürstenfeldbruck, Germany) with the cationic concentration protocol provided by Scintomics. |
| Modular-Lab PharmTracer Eckert & Ziegler | vendor cassette | SPE | 64% | >95% | DOTATOC ABX | 34439784 2021 Biomolecules Automated radiosynthesis was performed on an Eckert & Ziegler Modular-Lab PharmTracer synthesis module using the Modular-Lab software (Eckert & Ziegler). - RCYs of 57% and 64% were obtained for [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTATOC, respectively. |
| FASTlab GE HealthCare | — | SPE | 54.03±2.45 decay-corrected | 97.86±0.51 | DOTATOC BCN Peptides, Barcelona, Spain | 25369268 2014 PLoS One Most of the synthesis was performed using an automated process programmed in a FastLab module (General Electric Healthcare). - the decay-corrected radiochemical yield (%) was 54.03±2.45, 66.13±3.35 and 67.81±3.12 |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | 82.2 ± 2.7% decay-corrected | 97.3 ± 0.0% | DOTATOC (Edotreotide) MedChemExpress | 41011146 2025 Pharmaceuticals (Basel) A Scintomics GRP-3V module (Scintomics, Fürstenfeldbruck, Germany) was used for the automated synthesis of [68Ga]Ga-DOTATOC in combination with a 2-bench cassette system - an average decay-corrected yield (d.c.y.) of 82.2 ± 2.7% based on the theoretical maximum gallium-68 activity of the generator at that time point |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | 88.3 ± 0.6% decay-corrected | 97.8 ± 1.3% | DOTATOC (Edotreotide) MedChemExpress | 41011146 2025 Pharmaceuticals (Basel) A Scintomics GRP-3V module (Scintomics, Fürstenfeldbruck, Germany) was used for the automated synthesis of [68Ga]Ga-DOTATOC in combination with a 2-bench cassette system - corresponding to an average decay-corrected yield of 88.3 ± 0.6% |
| — | — | SPE | 34.4 ± 21.3% 0.6 nmol decay-corrected | — | DOTATOC Bachem, Bubendorf, Switzerland | 22682112 2012 EJNMMI Res |
| FASTlab 2 GE HealthCare | custom manifold | HPLC | 48.9 decay-corrected | 97.98 | Ga-DOTATOC acetate ABX | 40353471 2025 Curr Radiopharm the synthesis of [68Ga]Ga-DOTA-TOC was performed by FASTlab2 developer system - achieving a synthesis yield percentage (corrected for decay) of an average value of 48.9% |
| Kit-based preparation Advanced Accelerator Applications | vendor cassette | — | — | — | edotreotide (Somakit TOC) Advance Accelerator Applications, Italy | 40353471 2025 Curr Radiopharm 5 mL of [68Ga]GaCl3 was eluted through metal-free materials into a Somakit TOC® (40 mg of edotreotide) vial (Advance Accelerator Applications, Italy) |
| iQS-TS ITG (Isotope Technologies Garching) | vendor cassette | SPE | 62.6 | 99.1 | DOTATOC | 34658552 2021 Indian J Nucl Med Hot cell to house 68Ga iQS-TS Synthesis module, ITG, Germany - The average % synthesis yield and average % radiochemical purity obtained over all the synthesis were 62.6 (±2.3) and 99.1 (±0.2) %, respectively |
| Kit-based preparation Novartis | vendor cassette | — | — | 98.9 ± 0.7% by rTLC; 93.1 ± 1.4% by rHPLC | edotreotide Novartis | 42344682 2026 World J Nucl Med Radiolabeling experiments were conducted using commercial SOMAKIT-TOC (edotreotide) kits. |
| Kit-based preparation Novartis | vendor cassette | — | — | 98.9 ± 1.1% by rTLC; 91.6 ± 1.0% by rHPLC | edotreotide Novartis | 42344682 2026 World J Nucl Med a full kit vial was reconstituted with 2 mL of WFI... two 68 Ge/ 68 Ga generators were connected to the kit vial and eluted sequentially, directly into the vial |
| Kit-based preparation Novartis | vendor cassette | — | — | 99.0 ± 0.6% Aliquot1: rTLC, 91.1 ± 3.4% rHPLC; Aliquot2: 97.6 ± 0.9% rTLC, 90.8 ± 2.3% rHPLC | edotreotide Novartis | 42344682 2026 World J Nucl Med a kit vial was reconstituted with 6.2 mL of WFI... to obtain two equal aliquots. The first radiolabeling was performed immediately on one aliquot, following the steps described in Procedure 1. |
| Kit-based preparation Novartis | vendor cassette | — | — | 95.6 ± 1.4% Aliquot1: rTLC, 87.2 ± 3.4% rHPLC; Aliquot2: 97.2 ± 3.4% rTLC, 89.6 ± 3.0% rHPLC | edotreotide Novartis | 42344682 2026 World J Nucl Med the kit vial was reconstituted and divided into two aliquots as described in Procedure 3. Both aliquots were then radiolabeled on the same day... using the two-generator preparation method detailed in Procedure 2. |
| Scintomics GRP / GRP-3V | vendor cassette | SPE | 62 | >98% for 68Ga-DOTATOC | DOTA0-(Phe1-Tyr3)-octreotide | 41824275 2026 EJNMMI Radiopharm Chem an automated synthesis module (Scintomics GRP®, Fürstenfeldbruck, Germany) - assuming a reference radiolabelling yield of 62% |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | 82.2 ± 2.7% decay-corrected | 97.3 ± 0.0% | DOTATOC (Edotreotide) MedChemExpress | 41011146 2025 Pharmaceuticals (Basel) A Scintomics GRP-3V module (Scintomics, Fürstenfeldbruck, Germany) was used for the automated synthesis of [68Ga]Ga-DOTATOC - average decay-corrected yield (d.c.y.) of 82.2 ± 2.7% |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | 88.3 ± 0.6% decay-corrected | 97.8 ± 1.3% | DOTATOC (Edotreotide) MedChemExpress | 41011146 2025 Pharmaceuticals (Basel) A Scintomics GRP-3V module (Scintomics, Fürstenfeldbruck, Germany) was used for the automated synthesis of [68Ga]Ga-DOTATOC - corresponding to an average decay-corrected yield of 88.3 ± 0.6% |
| Manual synthesis | — | SPE | 60.81 ± 1.96% | >97% | DOTATOC acetate (precursor D) / DOTATOC…DOTATOC acetate (precursor D) / DOTATOC acetate salt (precursor E) ABX | 40941986 2025 Molecules DOTA-TOC precursor in 1 mL acetate buffer was added to a vial containing about 5 mL of gallium-68 chloride. The reaction mixture was placed in a heating block preheated to 95 °C and heated for 10 min. - The obtained yields were 60.81 ± 1.96% for the first precursor and 54.15 ± 0.40% for the second |
| Kit-based preparation Novartis | vendor cassette | none | 54.15 ± 0.40% | >97% | SomaKit TOC Novartis | 40941986 2025 Molecules The labeling procedure of the precursor F was performed according to the standard kit manufacturer’s instruction. - The obtained yields were 60.81 ± 1.96% for the first precursor and 54.15 ± 0.40% for the second |
| miniAllinOne Trasis | vendor cassette | — | — | 99.21% | EDOTREOTIDE (DOTA-TOC) Advanced Accelerator Applications, Rueil-Malmaison, France | 40358768 2025 EJNMMI Radiopharm Chem Radiolabeling was carried out using the automated synthesizer MiniAiO® (Trasis SA, Ans, Belgique) |
| FASTlab 2 GE HealthCare | custom manifold | HPLC | 48.9 decay-corrected | 97.98 | Ga-DOTATOC acetate ABX | 40353471 2025 Curr Radiopharm the synthesis of [68Ga]Ga-DOTA-TOC was performed by FASTlab2 developer system according to the Guidelines on Good Radiopharmacy Practice (cGRPP) - with a decay-corrected yield (time of synthesis: 40 minutes) from an average minimum of 45.1% to a maximum of 52.5% (Mean: 48.9%) |
| Kit-based preparation Advanced Accelerator Applications | — | — | — | — | Somakit TOC (edotreotide) Advance Accelerator Applications, Italy | 40353471 2025 Curr Radiopharm Following the Somakit TOC® SmPC (Summary of Product Characteristics), 5 mL of [68Ga]GaCl3 was eluted through metal-free materials into a Somakit TOC® (40 mg of edotreotide) vial (Advance Accelerator Applications, Italy) |
| FASTlab 2 GE HealthCare | custom manifold | none | — | 97.81 | DOTA-(Tyr3)-octreotide acetate (DOTA-TOC) Fischer Scientific | 39598846 2024 Molecules Automated labeling of the precursor was accomplished using a FASTLab 2 synthesizer. |
| Modular-Lab PharmTracer Eckert & Ziegler | vendor cassette | — | — | — | DOTA-TOC piCHEM, Raaba-Grambach, Austria | 39464654 2024 Front Nucl Med [68Ga]Ga-DOTA-TOC was synthesized in an automatic Modular-Lab Pharm Tracer module connected to a 68Ge/68Ga-generator IGG100 (Eckert & Ziegler), following the synthesis template and kit reagents of the manufacturer. |
| Manual synthesis | — | SPE | 78 ± 15% | >99% | DOTA-TOC | 38675474 2024 Pharmaceuticals (Basel) [68Ga]Ga-DOTA-TOC was synthesized with slight modifications of the described production method [32,33]. - Radiochemical yield was 78 ± 15% (n = 5) |
| Manual synthesis | — | SPE | — | — | DOTA-TOC | 38346097 2024 J Med Chem Identical procedures were used to synthesize 68Ga-DOTA-TOC as the positive control. |
| iMiDEV PMB-Alcen | vendor cassette | SPE | 46 ± 7% decay-corrected | 99.6 ± 0.2% HPLC | DOTA-TOC MedChemTronica, Sollentuna, Sweden | 38091157 2023 EJNMMI Radiopharm Chem Microfluidic cassette-based iMiDEV™ radiosynthesizer - For [68Ga]Ga-DOTA-TOC, RCYdc was 46 ± 7% (n = 3) |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | — | — | DOTATOC ABX | 35889351 2022 Molecules the automated synthesis module Scintomics GRPTM (Scintomics GmbH, Fürstenfeldbruck, Germany) |
| Manual synthesis | — | none | — | >95% | DOTA-TOC ABX | 31123943 2019 EJNMMI Res A solution of 68Ga(OAc)3 in acetate buffer was added to 20 nmol of each peptide. The reaction mixture was shaken for 10 min at 80 °C to afford [68Ga]Ga-DOTA-TOC or at 20 °C for 10 min to afford [68Ga]Ga-DATA-TOC. |
| Manual synthesis | — | HPLC+SPE | 61% decay-corrected | >98% | DOTATOC In-house / non-commercial (various) | 29503845 2017 EJNMMI Radiopharm Chem heated in a microwave oven (catalog number: DMW7700WDB, Danby Appliance, Findlay, Ohio) - 61 ± 5, 62 ± 8 and 68 ± 13% respectively, n = 3 |
| FASTlab GE HealthCare | — | SPE | 54.03 decay-corrected | 97.86 | DOTATOC BCN Peptides, Barcelona, Spain | 25369268 2014 PLoS One Most of the synthesis was performed using an automated process programmed in a FastLab module (General Electric Healthcare). - the decay-corrected radiochemical yield (%) was 54.03±2.45, 66.13±3.35 and 67.81±3.12 |
| — | — | HPLC | 64.68 | 98 ± 0.22% | DOTATOC | 35190517 2022 Nucl Med Commun |
| — | — | none | >80% | — | DOTATOC | 22755505 2012 Bioconjug Chem The NaCl method was further evaluated using an automated fluid handling system - radiochemical yields greater than 80% |
| — | — | none | >65% | >99% | DOTATOC | 22755505 2012 Bioconjug Chem The NaCl method was further evaluated using an automated fluid handling system and it routinely facilitates radiochemical yields in excess of 65% in less than 15 min, with radiochemical purity consistently greater than 99% for the preparation of (68)Ga-DOTATOC. - routinely facilitates radiochemical yields in excess of 65% in less than 15 min |
| — | — | SPE | ~60% decay-corrected | — | DOTA-Tyr-octreotide (DOTATOC) | 17901771 2007 Nucl Med Commun A fully automated radiopharmaceutical synthesis device based on a modular concept for remote-controlled processing was developed and evaluated for a number of DOTA-derivatized peptides. - Automated synthesis resulted in overall decay-corrected reaction yields of about 60% within 10 min. |
| GAIA Elysia-Raytest | — | — | — | — | DOTA-TOC | 31845408 2020 J Labelled Comp Radiopharm utilizing a cassette module (GAIA; Elysia-Raytest; Germany) with a manual setup |
| Manual synthesis n/a | — | — | — | — | DOTA-TOC | 31845408 2020 J Labelled Comp Radiopharm manual setup for routine clinical production |
| Kit-based preparation n/a (commercial cold kit, various vendors) | — | — | — | — | Somakit TOC | 30636620 2019 Curr Radiopharm Somakit TOC® is a radiopharmaceutical kit registered in the European Union for the preparation of [68Ga]Ga-DOTA-TOC |
| — | — | SPE | 54.4 ± 2.3 % | 96.94 ± 0.74 % | DOTA-TOC | 29745348 2018 Curr Radiopharm We reported the [68Ga]Ga-DOTA-TOC production by automated cassette-based theranostic synthesizer system used in combination with a disposable GMP grade cassette system for cationic purification. - The average synthesis yield of radiopharmaceutical production was 54.4 ± 2.3 % and the radiochemical purity average was found 96.94 ± 0.74 %. |
| — | — | — | >80% | >98% | DOTATOC | 27103024 2016 J Nucl Med the generator system is contained within the fluidic labeling module - greater than 80% radiochemical yield |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study.2026 · Theranostics · Retrospective, multicentre
- A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N.2022 · Front Pediatr · Multicentre · Phase II
- Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs).2020 · ESMO Open · Multicentre · Phase I/II
- Diagnostic Performance of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.2025 · J Nucl Med · Prospective · Phase I/II
- Radio-Guided Surgery with a New-Generation β-Probe for Radiolabeled Somatostatin Analog, in Patients with Small Intestinal Neuroendocrine Tumors.2024 · Ann Surg Oncol · Prospective · Phase II
- Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial.2022 · Pharmaceutics · Prospective · Phase II
- Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of 68Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy.2021 · Mol Imaging Biol · Prospective
- Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid 68Ga-DOTATOC PET/MRI.2021 · Eur J Radiol · Prospective
- Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.2021 · Clin Nucl Med · Prospective
- Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.2021 · J Nucl Med · Prospective
Show all 148 clinical studies
- Inflammation-Based Index and 68Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC.2020 · J Nucl Med · Prospective · Phase II
- Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.2018 · J Nucl Med · Prospective · Phase II
- 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.2018 · J Formos Med Assoc · Prospective
- Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT.2017 · Eur Radiol · Prospective
- Diagnosis and workup of 522 consecutive patients with neuroendocrine neoplasms in Switzerland.2014 · Swiss Med Wkly · Prospective
- Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.2013 · Recent Results Cancer Res · Prospective
- 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.2007 · J Nucl Med · Prospective
- A 30-year institutional experience of insulinoma management at a tertiary care center: a case series.2026 · Gland Surg · Retrospective
- Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [90Y]Y-DOTATOC in patients with refractory meningioma: a single-centre experience.2026 · Eur J Nucl Med Mol Imaging · Retrospective
- SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [68Ga]Ga-DOTATOC and [68Ga]Ga-SSO120 with [18F]FDG PET.2026 · J Nucl Med · Retrospective
- Estimation of split renal function on PET using the SSTR-targeting radioligands [18F]SiTATE, [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-TOC in a theranostic setting.2026 · Eur J Nucl Med Mol Imaging · Retrospective
- Shifts in Urbanicity-Based Access to Radiotracers for Neuroendocrine Tumors.2026 · J Am Coll Radiol · Retrospective
- Carotid plaque inflammation and calcification on somatostatin receptor PET/CT imaging predict stroke and major adverse cardiovascular events.2026 · Eur Heart J Cardiovasc Imaging · Retrospective
- Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy.2026 · Eur J Nucl Med Mol Imaging · Retrospective
- Ga-68-Edotreotide PET/CT SSTR Total Tumor Volume as a Predictor of Outcome in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors.2026 · Cancer Control · Retrospective
- Normal organ [68Ga]DOTATOC uptake during PRRT: challenging the assumption of stable background shaped by cold somatostatin analogues treatment.2026 · Eur J Nucl Med Mol Imaging · Retrospective
- Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.2026 · Eur J Nucl Med Mol Imaging · Retrospective
- Imaging-derived biomarkers from 68Ga-DOTATOC PET/CT scans to predict survival of patients with neuroendocrine tumors after PRRT with 177Lu-DOTATATE.2025 · Cancer Imaging · Retrospective
- SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors.2025 · Eur J Nucl Med Mol Imaging · Retrospective
- [18F]SiTATE-PET/CT for detection of pheochromocytomas and paragangliomas: comparison of biochemical secretion, genotype and imaging metrics.2025 · Eur J Nucl Med Mol Imaging · Retrospective
- [68Ga]-DOTATOC PET/CT Volumetric Parameters Reflect Metastatic Potential in Pancreatic Neuroendocrine Tumors.2025 · Cancers (Basel) · Retrospective
- Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy.2025 · Eur Radiol · Retrospective
- Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment.2024 · Eur J Nucl Med Mol Imaging · Retrospective
- Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.2023 · J Neurooncol · Retrospective
- Clinical significance of atypical 68Ga-DOTATOC prostatic uptake on PET/CT: A ten-year review.2023 · Hell J Nucl Med · Retrospective
- Somatostatin receptor activity assessed by 68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors.2023 · Eur J Nucl Med Mol Imaging · Retrospective
- Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors.2023 · Cancer Control · Retrospective
- Diagnostic Utility of Somatostatin Receptor 2A Immunohistochemistry for Tumor-induced Osteomalacia.2022 · J Clin Endocrinol Metab · Retrospective
- Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT.2022 · Cancers (Basel) · Retrospective
- [68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease.2022 · Eur J Nucl Med Mol Imaging · Retrospective
- Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from 68Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors.2022 · J Nucl Med · Retrospective
- Usefulness of 68Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia.2021 · Sci Rep · Retrospective
- Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient.2020 · BMC Cancer · Retrospective
- Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors.2020 · Nucl Med Commun · Retrospective
- Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors.2020 · Eur J Nucl Med Mol Imaging · Retrospective
- Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours.2019 · Nucl Med Biol · Retrospective
- Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.2019 · Pancreas · Retrospective
- Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.2019 · Neurosurg Focus · Retrospective
- Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.2019 · Clin Nucl Med · Retrospective
- Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours.2018 · Eur J Nucl Med Mol Imaging · Retrospective
- Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.2015 · Ann Nucl Med · Retrospective
- Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors.2013 · EJNMMI Res · Retrospective
- A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.2013 · Eur J Nucl Med Mol Imaging · Retrospective
- Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.2010 · Horm Metab Res · Retrospective
- High Somatostatin Receptor Expression in Alveolar Soft Part Sarcoma Detected by 68 Ga-DOTATOC PET/CT.2026 · Clin Nucl Med · Clinical study
- 68 Ga- DOTATOC PET/CT, 18 F-FDOPA, and 18 F-FDG PET/MR Findings in Growth Hormone-secreting Pituitary Adenoma.2025 · Clin Nucl Med · Clinical study
- A Rare Case of Retroperitoneal Angiolipoma Mimicking Paraganglioma on Multimodality Imaging.2025 · Clin Nucl Med · Clinical study
- Impact of hyperglycemia and antidiabetic medication on pancreatic uptake on [68Ga]Ga-DOTATOC PET/CT.2025 · Front Endocrinol (Lausanne) · Clinical study
- Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications.2025 · Eur J Nucl Med Mol Imaging · Clinical study
- First-in-human study of an optimized, potential kit-type, SSTR antagonist 68Ga-DATA5m-LM4 in patients with metastatic neuroendocrine tumors.2025 · Theranostics · Clinical study
- Impact of tissue-independent positron range correction on [68Ga]Ga-DOTATOC and [68Ga]Ga-PSMA PET image reconstructions: a patient data study.2025 · Eur J Nucl Med Mol Imaging · Clinical study
- Long-axial field-of-view PET/CT improves radiomics feature reliability.2025 · Eur J Nucl Med Mol Imaging · Clinical study
- Abnormal uptake related to the thyroid gland on somatostatin receptor-targeted PET imaging: reported prevalence and rate of thyroid malignancy and parathyroid adenomas.2024 · Endocr Connect · Clinical study
- Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.2024 · J Nucl Med · Clinical study
- Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis.2024 · J Nucl Med · Clinical study
- Atypical Presentation of Splenic Tissue Mimicking Neuroendocrine Tumor Relapse.2024 · Clin Nucl Med · Clinical study
- False-Negative 68 Ga-FAPI PET/CT in Pediatric Thyroid Medullary Carcinoma Seen With 68 Ga-DOTATOC PET/CT and 18 F-FDG PET/CT.2024 · Clin Nucl Med · Clinical study
- Tumour-induced osteomalacia: the long road to diagnosis and recovery.2024 · BMJ Case Rep · Clinical study
- Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis.2023 · Horm Metab Res · Clinical study
- DOTATOC PET/CT imaging of a typical carcinoid tumor in a human ex-vivo perfused lung lobe.2023 · Quant Imaging Med Surg · Clinical study
- Evaluation of [68Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space.2023 · J Nucl Med · Clinical study
- The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy.2023 · Strahlenther Onkol · Clinical study
- CT-derived body composition analysis could possibly replace DXA and BIA to monitor NET-patients.2022 · Sci Rep · Clinical study
- Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors.2022 · J Nucl Med · Clinical study
- Multiparametric 18F-FDG and 68GA-DOTATOC PET Imaging in Bone Metastatic Meningioma Before Radionuclide Therapy: Assessment of Tumor Heterogeneity.2022 · Clin Nucl Med · Clinical study
- Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by 68Ga-DOTATOC PET/CT.2021 · EJNMMI Res · Clinical study
- Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.2021 · Cancer Biother Radiopharm · Clinical study
- Incidental Finding of a Parotid Basal Cell Adenoma With High Tracer Uptake on 68Ga-DOTATOC PET/CT.2021 · Clin Nucl Med · Clinical study
- Comparison of diagnostic value of 68 Ga-DOTATOC PET/MRI and standalone MRI for the detection of intracranial meningiomas.2021 · Sci Rep · Clinical study
- Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake.2021 · Diagnostics (Basel) · Clinical study
- A Rapid and Safe Infusion Protocol for 177Lu Peptide Receptor Radionuclide Therapy.2021 · J Nucl Med · Clinical study
- Altered Biodistribution of 68Ga-DOTATOC.2021 · Clin Nucl Med · Clinical study
- High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.2021 · J Nucl Med · Clinical study
- Pearls and Pitfalls in Interpretation of 68Ga-DOTATOC PET Imaging.2020 · Clin Nucl Med · Clinical study
- 177Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal Carcinoma.2020 · Clin Nucl Med · Clinical study
- Adrenocorticotropic Hormone-Secreting Esthesioneuroblastoma with Ectopic Cushing's Syndrome.2020 · Yonsei Med J · Clinical study
- Lower 68 Ga-DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland-A proof-of-concept study.2020 · Clin Endocrinol (Oxf) · Clinical study
- Ectopic Corticotropin-Releasing Hormone-Secreting Pancreatic Neuroendocrine Tumor: Excellent Response of Liver Metastases to Peptide Receptor Radionuclide Therapy as Demonstrated by 68Ga-DOTATOC and 18F-FDG PET/CT Imaging.2020 · Clin Nucl Med · Clinical study
- Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors.2020 · J Clin Endocrinol Metab · Clinical study
- Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using 68Ga-DOTATOC and 68Ga-DOTATATE.2020 · J Nucl Med · Clinical study
- 68Ga-dotatoc vs. 18F-FDG vs. radiolabelled PSMA PET/CT in renal cancer patients.2019 · Ann Transl Med · Clinical study
- 68Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with 18F-DOPA PET/CT.2019 · Rev Esp Med Nucl Imagen Mol (Engl Ed) · Clinical study
- Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution.2019 · Mol Imaging Biol · Clinical study
- Successful Localization Using 68Ga-DOTATOC PET/CT of a Phosphaturic Mesenchymal Tumor Causing Osteomalacia in a Patient with Concurrent Follicular Lymphoma.2018 · Nucl Med Mol Imaging · Clinical study
- The influence of elevated hormone levels on physiologic accumulation of 68Ga-DOTATOC.2018 · Ann Nucl Med · Clinical study
- Joint estimation of activity and attenuation for PET using pragmatic MR-based prior: application to clinical TOF PET/MR whole-body data for FDG and non-FDG tracers.2018 · Phys Med Biol · Clinical study
- Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.2017 · Theranostics · Clinical study
- Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast.2017 · J Nucl Med · Clinical study
- Synchronous presentation of nasopharyngeal carcinoma and abdominal paraganglioma with avid 18F-FDG and 68Ga-DOTA-TOC uptake in PET/CT by both tumours.2016 · Nuklearmedizin · Clinical study
- Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.2016 · Nuklearmedizin · Clinical study
- Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study.2016 · Eur J Nucl Med Mol Imaging · Clinical study
- Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.2016 · Eur J Nucl Med Mol Imaging · Clinical study
- [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.2016 · Oncotarget · Clinical study
- Theranostic Applications of Lutetium-177 in Radionuclide Therapy.2016 · Curr Radiopharm · Clinical study
- 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.2015 · J Nucl Med · Clinical study
- Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.2015 · Eur J Nucl Med Mol Imaging · Clinical study
- Toward radioguided surgery with β- decays: uptake of a somatostatin analogue, DOTATOC, in meningioma and high-grade glioma.2015 · J Nucl Med · Clinical study
- SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.2015 · Mol Imaging Biol · Clinical study
- (68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma.2015 · Eur J Nucl Med Mol Imaging · Clinical study
- Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.2015 · Q J Nucl Med Mol Imaging · Clinical study
- ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.2014 · Eur J Nucl Med Mol Imaging · Clinical study
- Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging.2014 · BMC Cancer · Clinical study
- Etiology and clinical profile of patients with Cushing's syndrome: A single center experience.2014 · Indian J Endocrinol Metab · Clinical study
- Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.2014 · J Nucl Med · Clinical study
- ⁶⁸Ga-DOTATOC PET-CT in the localization of source of ectopic ACTH in patients with ectopic ACTH-dependent Cushing's syndrome.2014 · Clin Imaging · Clinical study
- Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.2014 · Thyroid · Clinical study
- (68) Ga- DOTA(0) -Tyr(3) octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours.2014 · Clin Endocrinol (Oxf) · Clinical study
- Growth hormone-releasing hormone-producing pancreatic neuroendocrine tumor in a multiple endocrine neoplasia type 1 family with an uncommon phenotype.2013 · Eur J Gastroenterol Hepatol · Clinical study
- Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.2013 · Q J Nucl Med Mol Imaging · Clinical study
- 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.2013 · Eur J Nucl Med Mol Imaging · Clinical study
- Comparison between F-18 fluorodeoxyglucose and Ga-68 DOTATOC in metastasized melanoma.2013 · Nucl Med Commun · Clinical study
- High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT.2013 · Recent Results Cancer Res · Clinical study
- Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience.2012 · J Oncol · Clinical study
- Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.2011 · Endocr Relat Cancer · Clinical study
- Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT.2010 · Mol Imaging Biol · Clinical study
- Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.2005 · J Nucl Med · Clinical study
- Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.2004 · Eur J Nucl Med Mol Imaging · Clinical study
- Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.2003 · Mol Imaging Biol · Clinical study
- Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.2001 · Eur J Nucl Med · Clinical study
- Pulmonary neuroendocrine tumour-associated ectopic Cushing's syndrome: diagnostic challenges and multidisciplinary management.2026 · Endocrinol Diabetes Metab Case Rep · Case report
- Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-concept.2026 · Clin Nucl Med · Case report
- Ectopic Cushing's syndrome in a patient with DIPNECH and metastatic lung carcinoid.2025 · Endocrinol Diabetes Nutr (Engl Ed) · Case report
- Modified cornstarch as an effective treatment for insulinoma-induced hypoglycemia: a case report.2025 · Eur J Clin Nutr · Case report
- Radiochemical purity and patient preparation: Key factors affecting the accuracy of 68Ga-DOTATOC PET/CT imaging in neuroendocrine tumors.2024 · Hell J Nucl Med · Case report
- Ectopic adrenocorticotrophic hormone syndrome in a 10-year-old girl with a thymic neuroendocrine tumor: a case report.2024 · BMC Endocr Disord · Case report
- Expression of somatostatin receptors in hemangioblastomas associated with von Hippel-Lindau disease as a novel diagnostic, therapeutic, and follow-up opportunity: A case report and literature review.2024 · Arch Endocrinol Metab · Case report
- Difficult Diagnosis and Management of Concealed Cushing.2024 · Endocr Metab Immune Disord Drug Targets · Case report
- Ectopic Cushing's syndrome from a corticotropin-releasing hormone-secreting medullary thyroid carcinoma: a rare pitfall of inferior petrosal sinus sampling.2023 · Endocrinol Diabetes Metab Case Rep · Case report
- Big insulin-like growth factor 2-producing multiple solitary fibrous tumors treated with debulking surgery: A case report.2023 · Front Endocrinol (Lausanne) · Case report
- Pituitary metastases from neuroendocrine neoplasms: case report and narrative review.2021 · Pituitary · Case report
- Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers.2021 · Front Endocrinol (Lausanne) · Case report
- PET Imaging of Meningioma Using the Novel SSTR-Targeting Peptide 18F-SiTATE.2021 · Clin Nucl Med · Case report
- 68Ga-DOTATOC PET/CT in Pleural Solitary Fibrous Tumors.2021 · Clin Nucl Med · Case report
- 68Ga-Prostate-Specific Membrane Antigen Uptake in a Pancreatic Neuroendocrine Tumor.2020 · Clin Nucl Med · Case report
- A Case Report of Insulinoma Relapse on Background Nesidioblastosis: A Rare Cause of Adult Hypoglycemia.2019 · J Clin Endocrinol Metab · Case report
- 68Ga-DOTA-TOC PET/CT of von Hippel-Lindau Disease.2019 · Clin Nucl Med · Case report
- Effective localization in tumor-induced osteomalacia using 68Ga-DOTATOC-PET/CT, venous sampling and 3T-MRI.2017 · Endocrinol Diabetes Metab Case Rep · Case report
- 68Ga-DOTATOC PET/CT Imaging in Solitary Fibrous Tumor of the Pleura.2017 · Clin Nucl Med · Case report
Precursor
- Common precursor
- DOTA-TOC PMID 38091157 (DOI 10.1186/s41181-023-00229-9)
- Suppliers seen in the literature
- MedChemTronica (Sollentuna, Sweden)
- Cited suppliers in indexed syntheses
- ABX, Advance Accelerator Applications, Advanced Accelerator Applications, Rueil-Malmaison, BCN Peptides, Bachem, Bubendorf, Fischer Scientific, In-house / non-commercial (various), MedChemExpress, MedChemTronica, Sollentuna, Novartis, piCHEM
- Typical final purification
- SPE
Need this precursor?We can point you to suppliers for [68Ga]Ga-DOTA-TOC, or handle the enquiry for you.
Get in touchQuality control Pharmacopoeial monograph
- Ph. Eur. monograph
- 2482 Gallium (68Ga) edotreotide injection
- USP monograph
- not verified the USP-NF monograph index is subscription-only and no public confirmation was found
How this set was arrived at. Base set per Ph. Eur. 0125 + monograph 2482. Ge-68 breakthrough + metal impurities: generator Ga-68 only. RECOMMEND ADD: molar activity / peptide content (saturable target).
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-DOTA-TOC.
Get in touchNotes
Added from reverse module search (stage 6); 26 article(s) with Ga-68. Also seen with Cu-61[1], Ga-67[1], Tb-161[1], Y-90[1] (too few articles for own row).